These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 16371460)
1. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Grbovic OM; Basso AD; Sawai A; Ye Q; Friedlander P; Solit D; Rosen N Proc Natl Acad Sci U S A; 2006 Jan; 103(1):57-62. PubMed ID: 16371460 [TBL] [Abstract][Full Text] [Related]
2. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines. Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615 [TBL] [Abstract][Full Text] [Related]
3. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212 [TBL] [Abstract][Full Text] [Related]
4. p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function. Grammatikakis N; Lin JH; Grammatikakis A; Tsichlis PN; Cochran BH Mol Cell Biol; 1999 Mar; 19(3):1661-72. PubMed ID: 10022854 [TBL] [Abstract][Full Text] [Related]
5. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model. Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571 [TBL] [Abstract][Full Text] [Related]
6. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Burger AM; Fiebig HH; Stinson SF; Sausville EA Anticancer Drugs; 2004 Apr; 15(4):377-87. PubMed ID: 15057143 [TBL] [Abstract][Full Text] [Related]
7. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Hostein I; Robertson D; DiStefano F; Workman P; Clarke PA Cancer Res; 2001 May; 61(10):4003-9. PubMed ID: 11358818 [TBL] [Abstract][Full Text] [Related]
9. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922. Wang CY; Guo ST; Wang JY; Yan XG; Farrelly M; Zhang YY; Liu F; Yari H; La T; Lei FX; Jin L; Zhang XD; Jiang CC Oncotarget; 2016 Aug; 7(31):49597-49610. PubMed ID: 27391062 [TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Clarke PA; Hostein I; Banerji U; Stefano FD; Maloney A; Walton M; Judson I; Workman P Oncogene; 2000 Aug; 19(36):4125-33. PubMed ID: 10962573 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Solit DB; Osman I; Polsky D; Panageas KS; Daud A; Goydos JS; Teitcher J; Wolchok JD; Germino FJ; Krown SE; Coit D; Rosen N; Chapman PB Clin Cancer Res; 2008 Dec; 14(24):8302-7. PubMed ID: 19088048 [TBL] [Abstract][Full Text] [Related]
12. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Karreth FA; DeNicola GM; Winter SP; Tuveson DA Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255 [TBL] [Abstract][Full Text] [Related]
13. Activity of the heat shock protein 90 inhibitor ganetespib in melanoma. Wu X; Marmarelis ME; Hodi FS PLoS One; 2013; 8(2):e56134. PubMed ID: 23418523 [TBL] [Abstract][Full Text] [Related]
14. Hsp90·Cdc37 Complexes with Protein Kinases Form Cooperatively with Multiple Distinct Interaction Sites. Eckl JM; Scherr MJ; Freiburger L; Daake MA; Sattler M; Richter K J Biol Chem; 2015 Dec; 290(52):30843-54. PubMed ID: 26511315 [TBL] [Abstract][Full Text] [Related]
15. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323 [TBL] [Abstract][Full Text] [Related]
16. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Schulte TW; Neckers LM Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771 [TBL] [Abstract][Full Text] [Related]
17. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma. Sharma A; Madhunapantula SV; Gowda R; Berg A; Neves RI; Robertson GP Am J Pathol; 2013 Apr; 182(4):1151-62. PubMed ID: 23416158 [TBL] [Abstract][Full Text] [Related]
18. Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins. Smith JR; de Billy E; Hobbs S; Powers M; Prodromou C; Pearl L; Clarke PA; Workman P Oncogene; 2015 Jan; 34(1):15-26. PubMed ID: 24292678 [TBL] [Abstract][Full Text] [Related]
19. Hsp90/p50cdc37 is required for mixed-lineage kinase (MLK) 3 signaling. Zhang H; Wu W; Du Y; Santos SJ; Conrad SE; Watson JT; Grammatikakis N; Gallo KA J Biol Chem; 2004 May; 279(19):19457-63. PubMed ID: 15001580 [TBL] [Abstract][Full Text] [Related]
20. Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte. Ota A; Zhang J; Ping P; Han J; Wang Y Circ Res; 2010 Apr; 106(8):1404-12. PubMed ID: 20299663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]